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ABSTRACT
Objectives: To characterise antimicrobial use (AMU)
per production stage in terms of drugs, routes of
application, indications, duration and exposed animals
in farrow-to-finish pig farms in Spain.
Design: Survey using a questionnaire on AMU during
the six months prior to the interview, administered in
face-to-face interviews completed from April to October
2010.
Participants: 108 potentially eligible farms covering
all the country were selected using a multistage
sampling methodology; of these, 33 were excluded
because they did not fulfil the participation criteria and
49 were surveyed.
Results: The rank of the most used antimicrobials per
farm and production stage and administration route
started with polymyxins (colistin) by feed during the
growing and the preweaning phases, followed by
β-lactams by feed during the growing and the
preweaning phases and by injection during the
preweaning phase.
Conclusions: The study demonstrates that the
growing stage (from weaning to the start of finishing)
has the highest AMU according to different quantitative
indicators (number of records, number of
antimicrobials used, percentage of farms reporting use,
relative number of exposed animals per farm and
duration of exposure); feed is the administration route
that produces the highest antimicrobial exposure based
on the higher number of exposed animals and the
longer duration of treatment; and there are large
differences in AMU among individual pig farms.
INTRODUCTION
One of the main forces for the selection of
antimicrobial (AM)-resistant bacteria in
people and animals is their exposure to AMs
(eg, Smith and others 2002). The purposes
of monitoring usage of AMs in animals are
manifold and have been reviewed elsewhere
(eg, Jensen and others 2004, Grave and
others 2006, Chauvin and others 2008).
Since the beginning of the twenty-ﬁrst
century, increased effort has been made to
accurately measure antimicrobial use (AMU)
in animals (eg, Jensen and others 2004,
Grave and others 2006). According to Bondt
and others (2013), from a theoretical point
of view, the best way to quantify the exposure
to AMs in a population is to closely monitor
the applied treatments of individual animals,
or at least of individual farms, and relate this
to the total population at risk.
At the European level, the ESVAC project
(European Medicines Agency 2012) is the
most valuable attempt to produce harmo-
nised AMU data in animals, but the project
has two main constraints on the data col-
lected: the ﬁgures come from sales and not
from consumption of AMs and they are not
disaggregated by animal species. However, the
next step in the ESVAC project is to develop
harmonised systems to collect data per species
and to develop harmonised units of measure-
ment. Other criticisms have also been pre-
sented (Bondt and others 2013). Nowadays,
there is a broad consensus that AMU data per
animal species are needed for proper under-
standing and analysis of AM exposure in
animals (eg, Callens and others 2012, Moreno
2012, Bondt and others 2013). In the words
of Callens and others (2012), in this context
the collection of more detailed and accurate
animal species level data implies the collec-
tion of data directly at the end-user level.
Intensive pig farming is one of the live-
stock activities having putative higher AMU.
Nevertheless, the lifespan of commercial fat-
tening pigs is about six to seven months and
covers different production stages (from
birth until weaning; postweaning and
growing phase; and ﬁnishing period) having
diverse needs of AMs (Jensen and others
2011). These dissimilar stages need add-
itional effort to properly characterise AMU
in the pig production.
In Spain, fattening pig production can
take place in different farm types. Among
these, 14 per cent were farrow-to-ﬁnish farms
(performing breeding, preweaning, growing
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and ﬁnishing at the same site) in the year of the study
(2010) and were chosen to take part in a survey with the
following objective: to characterise AMU per production
stage in terms of drugs, routes of application, indica-
tions, duration and exposed animals. A comparative ana-
lysis of some of the data belonging to the ﬁnishing stage
has been previously published (Moreno 2012).
MATERIAL AND METHODS
Questionnaire design, sampling and eligibility criteria
Detailed information about the questionnaire, the sam-
pling and the eligibility criteria has been previously pub-
lished (Moreno 2012). Brieﬂy, a 14-page questionnaire
consisting mainly of open questions was used in
face-to-face interviews completed from April to October
2010. Questions were referred to AMU during the six
months prior to the interview. Records of AM treatments
included administration route (in-feed, in-water and per
injection), growing phase (preweaning, growing and ﬁn-
ishing), name of commercial product (including pre-
mixes in feed medications), manufacturer, dose, length
of treatment, indication (therapeutic, prophylactic and
both (metaphylactic)), intended disease (respiratory,
digestive and others) and number of treated animals
during the last six month (Moreno 2012).
The sampling frame was obtained from the ofﬁcial
Spanish data records (currently Ministerio de
Agricultura, Alimentación y Medio Ambiente) updated
at January 2010. A multistage sampling methodology was
applied with peninsular, autonomic communities as the
primary sampling units and farms as the secondary sam-
pling units. The size of the sampling frame was 15
Autonomic Communities and 2,968 FtF farms (January
2010). Therefore, inclusion criteria were peninsular
farrow-to-ﬁnish farms ofﬁcially registered. Sample size
calculations (WinEpiscope 2.0) were based in the worse-
case scenario (eg, 50% expected relative frequency of
farms reporting AMU of any speciﬁc antimicrobial),
with 95% conﬁdence level, an expected error of 10%
and an inﬁnite population). These assumptions led to a
sample size calculation of 97 farms. An expected partici-
pation percentage of 90% was then used, to obtain a
ﬁnal sample size of 108 farms.
RESULTS
Study participation
As reported previously (Moreno 2012), of the 108 poten-
tially eligible farms, 33 (30.6 per cent) were excluded
because they did not fulﬁl the participation criteria
(a farrow-to-ﬁnish farm in full operation during at least
six months before the interview), resulting in 75 eligible
farms, of which 49 (65 per cent) were surveyed.
Main descriptive questionnaire-based data of surveyed
farms
The mean number of sows (n=49) was 389 (IQR, 131–
523); the mean number of ﬁnishers (n=49) was 1783
(IQR, 490–1982); the mean length in days of the pro-
duction cycle (n=47) was 191 (IQR, 170–195), distribu-
ted as preweaning (mean=26; IQR=24–28), growing
(mean=49; IQR=32–52) and ﬁnishing (mean=118;
IQR=104–124); 92 per cent of the farms produced stand-
ard white pigs, 6 per cent produced Iberian pigs and 2
per cent both types of pigs.
Descriptive analysis of records of AMU
We collected 564 records reporting use of AMs and/or
zinc oxide and identiﬁed the use of 26 different AMs
belonging to 10 classes (AMCs): β-lactams (amoxicillin,
ampicillin, penicillin, ceftiofur and cefquinome), poly-
myxins (colistin), tetracyclines (doxycycline, tetracycline,
chlortetracycline and oxytetracycline), ﬂuoroquinolones
(enroﬂoxacin, marboﬂoxacin and danoﬂoxacin), linco-
samides (lincomycin), aminoglycosides/aminocyclitols
(streptomycin, gentamicin, neomycin, apramycin, framy-
cetin and spectinomycin), macrolides (tylosin, tilmico-
sin, tulathromycin, erythromycin and spiramycin),
pleuromutilins (tiamulin), potentiated sulphonamides
(sulphonamides and trimethoprim), and phenicols
(ﬂorphenicol).
Per production stage, the highest number of records
came from the growing phase (263, 47 per cent), fol-
lowed by the ﬁnishing (190, 34 per cent) and the pre-
weaning phases (111, 20 per cent). The highest ﬁgures
per administration route arose from injection (274, 49
per cent), followed by feed (175, 31 per cent) and water
medications (115, 20 per cent). Water medications were
not reported during the preweaning stage.
Combinations of two or more AMs (excluding zinc
oxide) were very frequent among feed medications (62
per cent), and scarce among water (9 per cent) and
injection medications (20 per cent). These data also
showed an elevated number of feed medicated records
containing zinc oxide that were mainly used in the pre-
weaning (63 per cent) and growing phases (65 per
cent).
Of the 564 records, 515 (91.3 per cent) had informa-
tion regarding the indication of the AM (104 from pre-
weaning, 238 from growing and 173 from ﬁnishing). A
prophylactic indication was in 34.2 per cent of the
records (176), whereas 65.8 per cent showed a thera-
peutic or metaphylactic use. According to these data,
prophylactic use decreased from the preweaning (49.0
per cent) and the growing (41.6 per cent) phases to the
fattening phase (15.0 per cent).
Records of therapeutic/metaphylactic indications were
mainly associated with the parenteral route (65.5 per
cent), followed by water administration (28.3 per cent).
The most used AMs for these indications by the paren-
teral route during all the production stages were
β-lactams (mainly amoxicillin and penicillin) and ﬂuoro-
quinolones (enroﬂoxacin).
By water, the most used AMs were amoxicillin, colistin
and doxycycline in the growing stage, and doxycycline,
lincomycin and colistin during the ﬁnishing period. By
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contrast, records for prophylactic use were most fre-
quent for medicated feed (70.5 per cent), colistin,
amoxicillin and zinc oxide being the most used.
Of the 564 records, 497 (88.1 per cent) had informa-
tion about the number of treated animals (88 from pre-
weaning, 244 from growing and 165 from ﬁnishing).
Considering group treatment as the administration of an
AM to all the pigs of the same production group
(Callens and others 2012) we recorded 199 of 497
group treatments (40 per cent); most of them were
administered via feed (145, 72.9 per cent) and fewer by
injection (34, 17.1 per cent) or water administration (20,
10 per cent), and fewer during the ﬁnishing phase (35/
165, 21.2 per cent) than during the preweaning (56/88,
62.5 per cent) or growing (108/244, 44.3 per cent)
phases.
The mean number of treated animals per 1000 animals
at risk was calculated only when ﬁgures of use in three or
more farms were available, and ranged as follows: for
feed administration, from 982 per 1000 (polymyxins) to
976 per 1000 (β-lactams) in the preweaning stage, from
1000 per 1000 (lincosamides, tetracyclines, aminoglyco-
sides, pleuromutilins, sulphonamides-trimethoprim and
macrolides) to 982 per 1000 (β-lactams) in the growing
stage, and from 1000 per 1000 (β-lactams) to 680 per
1000 (pleuromutilins) in the ﬁnishing stage; for water
administration, from 464 per 1000 (β-lactams) to 170 per
1000 (lincosamides) in the growing stage and from 670
per 1000 (β-lactams) to 238 per 1000 (polymyxins) in the
ﬁnishing stage; for injection, from 606 per 1000
(β-lactams) to 87 per 1000 (lincosamides) in the prewean-
ing stage, from 353 per 1000 (polymyxins) to 22 per 1000
(phenicols) in the growing stage and from 298 per 1000
(polymyxins) to 29 per 1000 (phenicols) in the ﬁnishing
stage.
Finally, 507 of the 564 records (89.9 per cent) also
had information regarding the duration of the
treatment (104 from preweaning, 232 from growing and
171 from ﬁnishing). These data were only analysed
under the farm-level approach presented below.
Analysis of AMU based on farm data
All the farms used at least one AM during the study
period. Table 1 summarises the AMCs detected per pro-
duction stage. The most used AMCs were β-lactams
(mainly amoxicillin) and polymyxins (colistin). The
median number of different AMCs used by farm and
production stage were as follows: 2 in the preweaning
stage (range 0–5), 4 in the growing phase (range 0–8), 3
in the ﬁnishing stage (range 1–8) and 5 in the full cycle
(range 2–9).
Analysis of the AMCs used during the three production
stages by farm reveals that 33 farms (67 per cent) used at
least one AM during the full production cycle (from pre-
weaning to ﬁnishing); of these, 14 (29 per cent) used two
different AMCs and 4 (8 per cent) used three different
AMCs (all included β-lactams and three polymyxins plus
ﬂuoroquinolones). When the analysis was restricted to oral
use (feed or water medication), 11 (22 per cent) farms
used the same AM during the full production cycle; of
these, 5 (10 per cent) used two different AMs (all but one
included polymyxins). The most used AMs during the full
production cycle were β-lactams (25 farms, 51 per cent),
polymyxins (9 farms, 18 per cent) and ﬂuoroquinolones
(9 farms, 18 per cent).
Analysis of indications
All the farms recognised at least one therapeutic treat-
ment and all but two at least one preventive treatment.
Table 2 summarises the indications detected per farm
and production stage. As obtained from the records,
farm AMU during the preweaning stage was more for
preventive (57 per cent of farms) than therapeutic (39
per cent) use; therapeutic (94 per cent) and preventive
TABLE 1: Farm-level figures of use of antimicrobials and zinc oxide in 49 Spanish farrow-to-finish pig farms per production
stage expressed as percentages of farms exposed (number of farms)
Antimicrobial classes
Preweaning stage
(1–26 days)
Growing stage
(27–75 days)
Finishing stage
(76–193 days)
Full cycle
(1–193 days)
Any 94 (46) 98 (48) 100 (49) 100 (49)
β-lactams 80 (39) 90 (44) 57 (28) 96 (47)
Polymyxins 65 (32) 80 (39) 37 (18) 90 (44)
Fluoroquinolones 29 (14) 53 (26) 41 (20) 63 (31)
Aminoglycosides 35 (17) 45 (22) 37 (18) 63 (31)
Tetracyclines 4 (2) 41 (20) 47 (23) 59 (29)
Lincosamides 10 (5) 33 (16) 39 (19) 53 (26)
Macrolides 4 (2) 18 (9) 22 (11) 33 (16)
Pleuromutilins 4 (2) 24 (12) 24 (12) 33 (16)
Sulphonamides-trimethoprim 2 (1) 18 (9) 8 (4) 27 (13)
Phenicols 2 (1) 6 (3) 14 (7) 16 (8)
Zinc oxide 57 (28) 73 (36) 16 (8) 84 (41)
β-lactams: amoxicillin, ampicillin, penicillin, ceftiofur and cefquinome; polymyxins: colistin; tetracyclines: doxycycline, tetracycline,
chlortetracycline and oxytetracycline; fluoroquinolones: enrofloxacin, marbofloxacin and danofloxacin; lincosamides: lincomycin;
aminoglycosides/aminocyclitols: streptomycin, gentamicin, neomycin, apramycin, framycetin and spectinomycin; macrolides: tylosin,
tilmicosin, tulathromycin, erythromycin and spiramycin; pleuromutilins: tiamulin; phenicols: florphenicol
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TABLE 2: Farm-level figures of indications for antimicrobial use in 49 Spanish farrow-to-finish pig farms per production stage
expressed as percentage of farms exposed (number of farms)
Indication
Preweaning stage
(1–26 days)
Growing stage
(27–75 days)
Finishing stage
(76–193 days)
Full cycle
(1–193 days)
Therapeutic 39 (19) 94 (46) 92 (45) 100 (49)
Digestive disorders 27 (13) 65 (32) 55 (27) 76 (37)
Respiratory disorders 12 (6) 65 (32) 78 (38) 80 (39)
Other disorders 10 (5) 39 (19) 18 (9) 49 (24)
Unspecified disorders 2 (1) 8 (4) 4 (2) 10 (5)
Preventive 57 (28) 86 (42) 43 (21) 96 (47)
Digestive disorders 43 (21) 73 (36) 35 (17) 86 (42)
Respiratory disorders 18 (9) 41 (20) 20 (10) 59 (29)
Other disorders 12 (6) 20 (10) 4 (2) 31 (15)
Unspecified disorders 6 (3) 12 (6) 10 (5) 18 (9)
TABLE 3: Farm-level figures of use of antimicrobials and zinc oxide in 49 Spanish farrow-to-finish pig farms per production
stage expressed as number of treated animals per 1000 animals at risk and percentages of farms exposed
Antimicrobial
classes
Administration
route
Preweaning stage
(1–26 days)
Growing stage
(27–75 days)
Finishing stage
(76–193 days)
Mean*
(na) %† (n)
mean
(na) % (n)
mean
(na) % (n)
Any Any 749 (46) 94 (46) 921 (48) 98 (48) 503 (48) 100 (49)
β-lactams Feed 418 (21) 43 (21) 552 (27) 57 (28) 82 (4) 8 (4)
Water 106 (11) 24 (12) 71 (5) 14 (7)
Injection 379 (30) 63 (31) 103 (36) 84 (41) 56 (21) 43 (21)
Polymyxins Feed 561 (28) 57 (28) 740 (36) 76 (37) 177 (9) 22 (11)
Water 85 (12) 27 (13) 58 (12) 24 (12)
Injection 21 (6) 14 (7) 29 (4) 8 (4) 24 (4) 8 (4)
Fluoroquinolones Injection 23 (12) 29 (14) 136 (24) 53 (26) 60 (17) 41 (20)
Tetracyclines Feed 41 (2) 4 (2) 184 (9) 18 (9) 124 (8) 16 (8)
Water 88 (13) 27 (13) 132 (21) 43 (21)
Injection 5 (1) 2 (1) 2 (1) 2 (1) 7 (3) 6 (3)
Aminoglycosides Feed 20 (1) 2 (1) 204 (10) 20 (10) 76 (4) 8 (4)
Water 30 (6) 14 (7) 35 (6) 12 (6)
Injection 115 (16) 33 (16) 19 (13) 29 (14) 14 (8) 24 (12)
Lincosamides Feed 41 (2) 4 (2) 265 (13) 27 (13) 56 (3) 8 (4)
Water 14 (4) 8 (4) 82 (13) 27 (13)
Injection 5 (3) 6 (3) 7 (3) 6 (3) 17 (7) 18 (9)
Macrolides Feed 83 (4) 10 (5) 49 (3) 10 (5)
Water 20 (1) 2 (1) 20 (1) 2 (1)
Injection 22 (2) 4 (2) 23 (4) 8 (4) 26 (6) 12 (6)
Pleuromutilins Feed 20 (1) 2 (1) 146 (7) 16 (8) 83 (6) 12 (6)
Water 2 (1) 2 (1) 2 (1)
Injection 10 (1) 2 (1) 30 (5) 12 (6) 27 (6) 14 (7)
Sulphonamides-trimethoprim Feed 104 (5) 12 (6)
Water 18 (2) 4 (2)
Injection 60 (1) 2 (1) 4 (2) 3 (3) 8 (4)
Phenicols Injection 2 (1) 2 (1) 1 (3) 6 (3) 4 (7) 14 (7)
Zinc oxide Feed 571 (28) 57 (28) 735 (36) 73 (36) 163 (8) 16 (8)
*Number of treated animals per 1000 animals at risk
†Percentage of farms exposed
na: number of farms having data of treated animals; n: number of farms reporting use; β-lactams: amoxicillin, ampicillin, penicillin, ceftiofur
and cefquinome; polymyxins: colistin; tetracyclines: doxycycline, tetracycline, chlortetracycline and oxytetracycline; fluoroquinolones:
enrofloxacin, marbofloxacin and danofloxacin; lincosamides: lincomycin; aminoglycosides/aminocyclitols: streptomycin, gentamicin,
neomycin, apramycin, framycetin and spectinomycin; macrolides: tylosin, tilmicosin, tulathromycin, erythromycin and spiramycin;
pleuromutilins: tiamulin; phenicols: florphenicol
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(86 per cent) use increased during the growing phase
and the pattern shifted to therapeutic (92 per cent)
versus preventive (43 per cent) indications at the ﬁnish-
ing stage. The percentages of farms reporting AMU for
treatment of respiratory and digestive disorders during
ﬁnishing (78 and 55 per cent, respectively) and growing
(65 per cent) phases were high, and lower during the
preweaning stage (12 and 27 per cent, respectively). The
growing stage also produced the highest ﬁgures of farms
using AMs for prevention of digestive (73 per cent) and
respiratory (41 per cent) diseases. The use of zinc oxide
was mostly related to the prevention of digestive
disorders.
Analysis of AM exposure by farm
The ﬁgures for number of treated animals per record
were used to calculate farm-level ﬁgures of animals treated
per 1000 animals at risk (Table 3). In farms having several
records of the same AM in a production stage, only the
record having the highest number of treated animals was
used. In addition, for computing the summarised measure
of AMU, only the higher AM treatment was considered.
The mean values of this farm-level measure were high in
the three production stages, especially during the growing
(921 treated animals per 1000 animals at risk per farm)
and the preweaning stages (749 per 1000).
The rank of the most used AMs per farm and produc-
tion stage and administration route started with poly-
myxins (colistin) by feed in the growing (740 per 1000)
and the preweaning phases (561 per 1000), followed by
β-lactams by feed during the growing (552 per 1000)
and the preweaning phases (418 per 1000); next in the
ranking were the most used AMs by injection, which
were β-lactams in the preweaning phase, whereas the
most used AM by water were tetracyclines (mainly doxy-
cycline) during the ﬁnishing stage, ranked as twelfth.
These ﬁgures highlight the importance of the oral
route, especially feed administration, as contributing the
most to AM exposure: the highest ﬁgures of treated
animals per production stage were for feed administration
(among the 17 farm-level ﬁgures, there were more than
100 treated animals per 1000, 11 were by feed administra-
tion, 2 by water administration and 4 by injection).
Analysis of duration of AMU by farm
The data regarding the duration of AM treatments (89.2
per cent of the records) were used for calculating farm-
level ﬁgures of duration of AM use (Table 4). Because
there was no information regarding the timing of the
treatments belonging to the same production stage, only
the record of each AM having the longest duration was
used. The longest AM treatment on each farm, irrespect-
ive of the AM and the administration route, was chosen
to compute an overall measure of AM exposure length
per farm.
The longest durations corresponded to feed adminis-
tration, especially in the growing stage (lincosamides,
26 days; polymyxins, 24; β-lactams, 22). Nevertheless, we
only detected signiﬁcant differences (95 per cent)
between production stages for polymyxins and lincosa-
mides administered by feed, and β-lactams, lincosamides
and macrolides when administered by injection.
In addition to summarised data per production stage,
Table 4 also contains cumulative data of the total days of
exposition to AMCs. The ranking of the highest mean
values was as follows: pleuromutilins (39 days), polymyx-
ins (34), aminoglycosides (34), β-lactams (27) and linco-
samides (26), all of them by feed.
DISCUSSION
An increasing number of studies analysing AMU in com-
mercial pig production have been published since the
beginning of the twenty-ﬁrst century, but their objectives
and methodologies differ, and consequently comparative
analysis of the results was hampered.
Some authors have previously collected records of
AMU in pigs at the farm level (Rajic and others 2006,
Timmerman and others 2006, Casal and others 2007,
Rosengren and others 2007, 2008, Van der Fels-Klerx
and others 2011, Callens and others 2012), from practi-
tioners (Chauvin and others 2002, Jordan and others
2009) or using both sources (Merle and others 2012). In
the present study, farm-level records have been collected
and used for producing information about AMU using
two approaches: record based and farm based. Since the
number of records per farm varied in our study from 3
to 30 (0–15 in the preweaning stage, 0–10 in the
growing stage and 1–13 in the ﬁnishing stage), farm-
based analysis allowed circumventing repetitive informa-
tion belonging to some farms that could overestimate
various record-based ﬁgures of AMU; in addition, the
farm is the epidemiological unit of concern for AM
exposure and several authors (Timmerman and others
2006, Jordan and others 2009, Van der Fels-Klerx and
others 2011) have also detected large differences in
AMU among individual farms.
Some putative weaknesses (lower sample size than
designed and lower response percentage than expected)
of this study have been previously showed and discussed
(Moreno and others, 2012); nevertheless the medium
and larger farms were well represented and, conse-
quently the potential bias of the AMU estimation is
believed to be low since these farms produced the
majority of the commercial pigs coming from Spanish
farrow-to-ﬁnish farms. In addition, the methodologies
employed for collection, check, debug and analysis of
the data were the same for all the farms and production
stage, minimizing the bias in the comparative analysis of
these factors. The ﬁrst objective of this study was the
analysis of AMU by production stage and our results
showed that the growing stage (from 26 to 75 days of life
approx.) has the highest AMU. These results agree with
previous observations when ﬁnishers were compared
with younger animals in other European pig-producing
countries like Denmark (Jensen and others 2011),
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Belgium (Callens and others 2012) or Germany (Merle
and others 2012), and also Canada (Rajic and others
2006, Rosengren and others 2007, Rosengren and others
2008). It is interesting to note that these similar results
were obtained in spite of the different measures of AMU
employed for each study: animal daily doses (ADDs)
(Jensen and others 2011); treatment incidence (TI)
(Callens and others 2012); daily dose per animal year
(Merle and others 2012); percentages of farms using
AMs (Rajic and others 2006); or probabilities of expos-
ure (Rosengren and others 2007, Rosengren and others
2008). The higher use of AMs after the weaning of
piglets has been related to their most vulnerable status
to infectious diseases (Rajic and others 2006).
For drugs not used for the treatment of chronic dis-
eases, like AMs, usage should ideally be given in terms
of treatment rates per age group (Grave and others
2006). The number of exposed animals was thought to
best express AM selection pressure (Chauvin and others
2008) but cannot be calculated without the appropriate
data; for instance, it cannot be calculated from the
Danish Vetstat database because the number of treated
pigs was not recorded (Hybschmann and others 2011).
A proxy for this measure (Jensen and others 2011) is
the deﬁned ADD (introduced in the veterinary ﬁeld by
Jensen and others 2004)) and related measures, which
have been calculated in different pig studies (Bondt and
others 2013, Hybschmann and others 2011, Jensen and
others 2011, Van der Fels-Klerx and others 2011, Merle
and others 2012). ADD has also been used to calculate
TI in pigs (Timmerman and others 2006, Callens and
others 2012); nevertheless, these measures need prior
agreements on recommended dosages and average
animal weights before producing comparable results; for
instance, Merle and others (2012) used 12.5 kg for
piglets, 25 kg for weaners and 70.2 for fatteners; Jensen
TABLE 4: Farm-level figures of duration of use of antimicrobials and zinc oxide in 49 Spanish farrow-to-finish pig farms per
production stage expressed as days (mean, minimum and maximum)
Duration
Preweaning stage
(1–26 days)
Growing stage
(27–75 days)
Finishing stage
(76–193 days)
Full cycle*
(1–193 days)
Antimicrobial
classes
Administration
route
Mean
(na)
Min–
max
Mean
(na)
Min–
max
Mean
(na)
Min–
max
Mean
(na)
Min–
max
Any Any 9 (46) 1–30 24 (47) 2–60 12 (48) 1–75 44 (49) 6–102
β-lactams Feed 14 (16) 6–30 22 (25) 7–60 13 (4) 6–30 27 (30) 6–87
Water _ 6 (12) 4–9 5 (5) 4–7 8 (13) 4–14
Injection 1.8 (31) 1–4 2.5 (35) 1–6 2.4 (23) 1–4 5 (40) 1–11
Polymyxins Feed 14 (26) 6–30 24 (35) 7–55 22 (10) 6–75 34 (42) 6–89
Water 7 (13) 3–15 7 (12) 3–15 8 (21) 3–30
Injection 2.0 (7) 1–3 2.8 (4) 2–3 2.3 (4) 1–3 3.8 (9) 1–7
Fluoroquinolones Injection 2.5 (12) 1–3 2.6 (21) 1–5 2.8 (16) 1–4 4.6 (28) 1–9
Tetracyclines Feed 10 (1) 22 (6) 7–49 12 (7) 7–15 18 (12) 7–64
Water 7 (12) 4–30 6 (22) 4–36 9 (24) 4–36
Injection 3 (1) _ _ 2.5 (2) 2–3 2.5 (2) 2–3
Aminoglycosides Feed 15 (1) 27 (8) 7–60 41 (4) 15–75 34 (11) 7–75
Water 6 (7) 4–15 5 (7) 4–7 8 (10) 5–15
Injection 1.9 (15) 1–4 2.5 (11) 1–4 2.4 (9) 1–3 3.4 (21) 1–10
Lincosamides Feed 8 (3) 3–15 26 (12) 7–60 10 (4) 3–15 26 (14) 3–78
Water 5 (5) 4–6 6 (12) 4–7 7 (14) 4–12
Injection 2 (2) 1 (2) 2.8 (9) 1–4 2.8 (11) 1–4
Macrolides Feed 21 (4) 9–33 32 (3) 15–50 28 (6) 14–50
Water 7 (1) 7 (1) 14 (1)
Injection 1.5 (2) 1–2 1 (4) 3.1 (7) 1–5 2.6 (11) 1–5
Pleuromutilins Feed 15 (1) 36 (6) 20–55 22 (7) 6–60 39 (10) 6–70
Water 2 (1) 2 (1) 4 (1)
Injection 2 (1) 2 (5) 2.5 (6) 2–4 3.9 (7) 2–6
Sulphonamides/
trimethoprim
Feed 2 (1) 27 (5) 15–40 23 (6) 2–40
Water 4 (2) 4 (2)
Injection 3 (4) 3 (4)
Phenicols Injection 3 (1) 2 (1) 2.3 (7) 1–4 3 1–7
Zinc oxide Feed 15 (26) 6–30 23 (35) 5–60 10 (8) 7–15 33 (39) 7–69
*Sum of the longest treatment per production stage
na: number of farms having data of duration; β-lactams: amoxicillin, ampicillin, penicillin, ceftiofur and cefquinome; polymyxins: colistin;
tetracyclines: doxycycline, tetracycline, chlortetracycline and oxytetracycline; fluoroquinolones: enrofloxacin, marbofloxacin and danofloxacin;
lincosamides: lincomycin; aminoglycosides/aminocyclitols: streptomycin, gentamicin, neomycin, apramycin, framycetin and spectinomycin;
macrolides: tylosin, tilmicosin, tulathromycin, erythromycin and spiramycin; pleuromutilins: tiamulin; phenicols: florphenicol
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and others (2011) used 15 kg for weaners and 50 kg
for slaughter pigs; Bondt and others (2013) used 10 kg
for piglets and 50 kg for fattening pigs; and Callens
and others (2012) used a standard growth table from
birth to 10 weeks and the average daily weight for
fatteners.
The number of treated animals, although this does
not include AM dosage, is a straightforward and useful
parameter for AMU estimation, and its major practicabil-
ity of calculation at the farm level makes this measure
very useful, especially for the analysis of group treat-
ments since its information bias is very low. We are more
conﬁdent on the questionnaire-collected data when the
answer was ‘all’ the animals were treated in comparison
with records showing a ﬁgure, since these quantitative
data are more prone to recall bias, and the effect pro-
duced (over or underestimation of the true exposure)
cannot be properly addressed.
Some minor differences among producing stages were
also detected in our study regarding the most frequently
used AMCs. When analysing the percentages of farms
using AMs and the number of animals treated (Table 3)
showed that β-lactams and polymyxins were the most fre-
quently employed during the preweaning and the
growing phases, although the route of administration
was almost exclusively the feed for polymyxins, whereas
β-lactams were administered by feed and injection.
Besides the lower ﬁgures, the ﬁnishing stage showed that
the most employed AMs were polymyxins (by feed) and
tetracyclines (by water). Colistin and amoxicillin were
also the most used AMs for group treatments by the oral
route during the lifespan of commercial fattening pigs
in Belgium (Callens and others 2012); nevertheless, the
Belgian data for injectable medications showed higher
use of tulathromycin and lower use of enroﬂoxacin com-
pared with the Spanish data.
Differences in the most used AMs per production stage
have also been detected in Canadian pig production
(Rajic and others 2006), the most commonly reported
AMs being the following: in feed, the combination tetra-
cyclines/sulphonamides/penicillins in weaners, tylosin
and the combination tetracyclines/sulphonamides/peni-
cillins in growers, and tylosin and lincomycin in ﬁnishers;
by injection, penicillin, trimethoprim/sulphonamides
and oxytetracycline in weaners, and penicillin and oxy-
tetracycline in growers and ﬁnishers. Equally, data for
in-feed AMs in pigs in the USA (Apley and others 2012)
showed a different pattern of use, with tetracyclines
(chlortetracycline and oxytetracycline) and macrolides
(tilmicosin and tylosin) the most frequently employed
AMCs.
Callens and others (2012) reported that 93 per cent
of all the group treatments in Belgium were for prophy-
lactic purposes and only 7 per cent for metaphylactic
treatments; in addition, preventive treatments were
applied in 98 per cent of the farms. In the present
Spanish survey, 96 per cent of the pig farms also
employed preventive treatments; 188 of the 564 records
met the criterion of group treatment and included infor-
mation about indication; of these, 161 (85.6 per cent)
reported a preventive use. The distribution of these 188
group treatments per production stage in our study
showed that they were more frequently used during the
growing (54 per cent) and preweaning (28 per cent)
stages, and less during ﬁnishing (18 per cent), whereas
Callens and others (2012) reported 90 per cent of use
from birth to 10 weeks of age, and 10 per cent during
the fattening period.
Among these 188 group treatments, feed was the most
frequently employed administration route for preventive
indications, mainly containing combinations of colistin
and amoxicillin plus zinc oxide in the preweaning and
growing stages and different AMC combinations in the
ﬁnishing stage. The use of the parenteral route for pre-
vention was only relatively frequent during the prewean-
ing stage, being used mainly for administration of
β-lactams (amoxicillin, penicillin and ceftiofur); we
detected a low use of cephalosporins, which were the
most frequently parenterally administered AMs in the
Belgian study (Callens and others 2012).
Trends on the therapeutic use of AMs in pigs in
Denmark based on the data retrieved from the VetStat
database (Jensen and others 2011) showed differences
among age groups in the most frequently employed
AMs. In the sows/piglets group they were penicillins,
pleuromutilins, trimethoprim-sulphonamides and tetra-
cyclines; in weaners, they were tetracyclines, macrolides,
pleuromutilins and lincosamides; and in ﬁnishers they
were tetracyclines, pleuromutilins and macrolides.
Although there are differences in the AM groups
between studies (for instance, Jensen and others 2011
differentiated penicillins, aminopenicillins, penicillin
combinations and cephalosporins whereas we combined
all of these) some differences are clearly noted, espe-
cially the higher used of polymyxins (colistin) and ﬂuor-
oquinolones in our study and the higher use of
macrolides and pleuromutilins in the Danish study.
According to Casal and others (2007) the percentages
of farms in Spain using AMs for therapy in ﬁnishers
(2001–2003) were 94 per cent for respiratory diseases
and 90 per cent for digestive diseases, whereas the corre-
sponding ﬁgures in our 2010 study (78 per cent and 55
per cent) are lower; equally, preventive treatments were
detected in 58 per cent of the studied farms (2001–
2003) versus 43 per cent in the present study (2010).
Although the spatial coverage of both studies is not fully
equivalent, these ﬁgures could indicate a reduction of
AMU in ﬁnishers in Spain.
Although methodological differences preclude an in-
deep comparative analysis of the AMs most used for
treating gastrointestinal and respiratory bacterial infec-
tions, we detect some differences with other authors
(Jensen and others, 2011). Different studies have indi-
cated that AMs in pigs are mainly administered by the
oral route, although quantiﬁcation ﬂuctuates due to the
different measures employed. For instance, Timmerman
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and others (2006) reported 69 kg of AMs administered
orally versus 1 kg injected; Stevens and others (2007)
and Rajic and others (2006) reported that the most
common method of administering AMs was in the feed
(between 20 and 75 per cent, and between 80–100 per
cent of farms, respectively, depending on the production
system and/or the animal age); Merle and others (2012)
indicated that 92 per cent (based on applications) or 97
per cent (based on weight in kg) of all the AMs were
administered orally to pigs, whereas in our study this
percentage was lower (51.4 per cent of records);
Rosengren and others (2008) calculated probabilities of
exposure ranging between 0.17 and 0.78 for feed,
between 0 and 0.06 for water, and between 0.0003 and
0.04 for parenteral administration.
Although the length of AM treatment is another crit-
ical point for full understanding of AM exposure, we
have only found references to this topic in two studies
(Chauvin and others 2002, Stevens and others 2007).
French data (Chauvin and others 2002) on group treat-
ments were reported without repartition per administra-
tion route and production stage, whereas US data
(Stevens and others 2007) are separated according to
indication (growth promotion, prevention and therapy),
hindering comparative analysis with our results.
Nevertheless, noteworthy is the long duration of in-feed
treatments (ranging from 3 to 60 days), especially
during the growing stage (from 7 to 60 days); even con-
sidering the same production stage and administration
route, most of the AMs showed wide ranges in duration
of oral treatments (in feed, 12–24 days during prewean-
ing, 24–53 during growing and 8–69 during ﬁnishing; in
water, 2–26 during growing and 3–32 during ﬁnishing),
probably indicating a discretionary use. The cumulative
exposure data presented in Table 4 indicate that the
mean number of days of exposure during the lifespan of
a commercial pig is 44 days (23 per cent of the lifespan),
with a maximum value of 102 days (53 per cent of the
lifespan); these ﬁgures are conservative since all the
treatments for the same production phase on a farm
were assumed to be simultaneous, and consequently we
did not sum duration of treatments. These long-term
AM exposures were mostly due to feed medications and
highlight the role of feed medications as the most
involved in AM exposure in animals.
Callens and others (2012) discussed the contribution
of AM sales by veterinarians on their prescription behav-
iour (Maes and others 2010 showed that, in Belgium, 43
per cent of the income of pig veterinarians results from
the selling of medicines); nevertheless, the Spanish legis-
lation in Veterinary Medicines does not permit veterinar-
ians to carry out this commercial activity (Anon 2010).
To minimise the deleterious effects on public health
from AMU in animals, without unnecessary restrictions
of their therapeutic use for combating bacterial diseases
compromising the animal health and welfare, we need
to test tentative microbiological withdrawal times for
AMs, having in mind the role of suspension of AM
exposure on the ﬁtness and removal of AM-resistant bac-
teria in animals, especially from the intestinal micro-
biota. Food animal species like pigs which have a
relatively long lifespan and the lowest AMU during the
end of their lifespan would be good candidates for
testing this approach.
In conclusion, we previously showed that AMU in the
pig ﬁnishing period varies according to the production
system, being higher in ﬁnisher farms than in
farrow-to-ﬁnish-farms (Moreno 2012). Now, a national
survey based on data from questionnaires but from a
limited number of farms has studied AMU in
farrow-to-ﬁnish farms and demonstrated the following:
the growing stage (from weaning to the start of ﬁnish-
ing) has the highest AMU according to different quanti-
tative indicators (number of records, number of AMs
used, percentage of farms reporting use, relative
number of exposed animals per farm and duration of
exposure); feed is the administration route that pro-
duces the highest AM exposure based on the higher
number of exposed animals and the longer duration of
treatment; and there are large differences in AMU
among individual pig farms.
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